← All trials
NCT05548088
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2022
- Primary completion
- Dec 30, 2023
- Completion date
- Aug 30, 2024
- First posted
- Sep 21, 2022
- Last posted
- Sep 21, 2022
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Peking UniversityLead sponsor
- Peking UniversityOverall official - principal investigator
- Peking UniversityReponsible party - principal investigator
- Beijing Qingyi Taike Pharmaceutical Technology Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.